Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances

Obesity Clinical Trial

Official title:

Acute and Chronic Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02949115
• Other study ID #: COL00729
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 2016
• Est. completion date: June 2019

Study information

• Verified date: November 2018
• Source: Colorado State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aside from aging, numerous factors increase the risk for developing cardiovascular disease (CVD) including diet and nutrition. High-fat meal consumption induces postprandial vascular endothelial dysfunction and other cardiometabolic disturbances (e.g. dyslipidemia and hyperglycemia) in normal weight individuals and is exacerbated in overweight/obese individuals. These postprandial responses are likely largely due to activation of pro-inflammatory and pro-oxidant pathways. Given that much of the day is spent in the postprandial state, this may further impair cardiovascular health in aging overweight/obese individuals. Interventions that attenuate these responses are needed. Red beetroot (Beta vulgaris L.) is an excellent source of bioactive compounds including nitrate, flavonoids, phenolic acids, betalains, carotenoids, and ascorbic acid. These bioactive compounds and their metabolites have been shown to have antioxidative, anti-inflammatory, and cardiovascular-protective effects. These effects, particularly the cardiovascular-protective effects, have been primarily attributed to its high content of nitrate since it is converted to nitric oxide independent of the vascular endothelium via the enterosalivary nitrate-nitrite-nitric oxide pathway. However, red beetroot juice contains a number of other potentially beneficial bioactive compounds and few studies have aimed to determine whether these compounds work independently, additively, or synergistically in exerting these effects. Given the findings of previously conducted research in the broad area of red beetroot juice consumption and human health, it can be suggested that: 1) acute red beetroot juice consumption may prevent or attenuate the adverse postprandial responses to consuming a high-fat meal in individuals with exaggerated responses; and 2) chronic consumption of red beetroot may improve underlying factors contributing to these exaggerated responses. Accordingly, this project aims to: 1) investigate the efficacy of acute and chronic whole red beetroot juice consumption compared with its bioactive components in attenuating postprandial vascular endothelial dysfunction and adverse cardiometabolic responses to a high-fat meal; and 2) to gain insight into the underlying mechanisms responsible.

Description:

This is a randomized, double-blind, placebo-controlled, 4-period, 4-week crossover pilot clinical trial consisting of 2 postprandial tests for each period. Overweight or obese postmenopausal women and men aged 40 to 65 will be recruited from the greater Fort Collins, CO area. After telephone prescreening, participants will report to the study site for their first visit (Screening) where they will receive verbal and written explanation of the project, provide informed consent, followed by screening assessments. Qualified participants will be scheduled for a baseline visit and randomly assigned to their respective treatments. On the second visit (Baseline) following an overnight fast, anthropometrics and blood pressure will be measured and diet and physical activity records will be collected. Subjects will ingest their respective treatment 10 min prior to consuming the high-fat test meal. Various assessments will be performed and samples collected prior to and up to 4 hours post-meal consumption. At the third visit (Final), all assessments and sample collections will be repeated at the same time points but 24 hours after consuming the last dose of their respective treatments to test chronic rather than acute effects. Subjects will undergo a 4-week washout period before crossing over to the next treatment period. This will be repeated for all 4 treatments.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: June 2019
• Est. primary completion date: August 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Postmenopausal women and men

• BMI between 25 and 40 kg/m2

Exclusion Criteria:

• Hypertension, cardiovascular disease, diabetes, cancer, or kidney, liver, or pancreatic disease

• Individuals taking gastroesophageal reflux, antihypertensive, hypoglycemic, lipid-lowering, hormone replacement, erectile dysfunction medications or nitrates

• Participating in a weight loss program or actively trying to lose weight

• Smokers

• Heavy drinkers (> 3 drinks on any given occasion and/or > 7 drinks/week for women, or > 4 drinks on any given occasion and/or > 14 drinks/week for men)

• Allergy to meals/treatments

• Consuming > 2 servings red beetroot or beetroot juice/wk

Related Conditions & MeSH terms

• Aging
• Menopause
• Obesity
• Overweight

Intervention

Dietary Supplement:
• 70 mL red beetroot juice
1x daily intake of 70 mL red beetroot juice
• 70 mL red beetroot juice without nitrate
1x daily intake of 70 mL red beetroot juice without nitrate
• 70 mL placebo drink plus potassium nitrate
1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
• 70 mL placebo drink
1x daily intake of 70 mL placebo control drink

Locations

Country	Name	City	State
United States	Department of Food Science and Human Nutrition, Colorado State University	Fort Collins	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
Colorado State University	United States Department of Agriculture (USDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Blood polyphenols and polyphenol metabolites	Blood polyphenols and metabolites will be measured by mass spectrometry at 0, 1, 2 and 4 hours post-meal consumption.	0, 1, 2 and 4 hours post-meal consumption at baseline and 1 month for each treatment period.
Other	Urinary polyphenols and polyphenol metabolites	Urinary polyphenols and metabolites will be measured by mass spectrometry at 0 and 24 hours post-meal consumption.	0 and 24 hours post-meal consumption at baseline and 1 month for each treatment period.
Other	Oral and gut microbiome	The role of the oral and gut microbiome in efficacy of treatments at baseline and over time will be evaluated.	Pre-meal consumption at baseline and 1 month for each treatment period.
Primary	Vascular endothelial function	Vascular endothelial function will be assessed using reactive hyperemia index (EndoPAT) 0 and 4 hours post-meal consumption.	0 and 4 hours post-meal consumption at baseline and 1 month for each treatment period.
Secondary	Blood glucose, insulin, and indices of insulin sensitivity and resistance	Blood glucose and insulin will be measured by biochemical analysis at 0 and 1, 2, and 4 hours post-meal consumption and indices of insulin sensitivity and resistance will be calculated.	0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.
Secondary	Blood triglycerides	Blood triglycerides will be measured by biochemical analysis at 0 and 1, 2, and 4 hours post-meal consumption.	0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.
Secondary	Blood pressure	Peripheral and central blood pressure measured by an automatic sphygmomanometer and SphygmoCor at 0 and 1, 2, and 4 hours post-meal consumption.	0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period
Secondary	Heart rate	Heart rate will be measured by an automatic sphygmomanometer and SphygmoCor at 0 and 1, 2, and 4 hours post-meal consumption.	0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.
Secondary	Arterial stiffness	Arterial stiffness will be assessed as carotid-femoral pulse wave velocity and augmentation index (using SphygmCor and EndoPAT) at baseline and 1 month periods (pre-meal consumption).	Pre-meal consumption at baseline and 1 month for each treatment period.
Secondary	Nitric oxide biomarkers	Nitric oxide metabolites and molecules involved in nitric oxide production and bioavailability will be evaluated in saliva, blood, peripheral blood mononuclear cells, and biopsied venous endothelial cells at 0 and 1, 2, and 4 hours post-meal consumption.	0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.
Secondary	Oxidative stress biomarkers	Biomarkers of oxidative stress will be evaluating in peripheral blood mononuclear cells and biopsied venous endothelial cells at 0 and 1, 2, and 4 hours post-meal consumption.	0 and 4 hours post-meal consumption at baseline and 1 month for each treatment period.
Secondary	Pro-inflammatory biomarkers	Biomarkers of inflammation will be evaluating in peripheral blood mononuclear cells and biopsied venous endothelial cells at 0 and 4 hours post-meal consumption.	0 and 4 hours post-meal consumption at baseline and 1 month for each treatment period.